Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

and a corticosteroid as a first-line therapy for metastatic castration-resistant prostate cancer (mCRPC). However, the panel agreed with the FDA reviewer’s position that the regimen had not yet ...

Docetaxel plus prednisone as a first-line chemotherapy ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

Men with metastatic castration-resistant prostate cancer (mCRPC ... use of drugs known to reduce ICI efficacy, such as steroids and antibiotics. "Considering the prevailing negativity of multiple ...

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets ...